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Abstract 
Background 
Despite increased INSTI use, limited large-scale, real-life data exists on INSTI uptake 
and discontinuation. 
Setting 
International multicohort collaboration. 
Methods 
RESPOND participants starting dolutegravir (DTG), elvitegravir (EVG) or raltegravir 
(RAL) after 1/1/2012 were included. Predictors of INSTI used were assessed using 
multinomial logistic regression. Kaplan Meier and Cox proportional hazards models 
describe time to and factors associated with discontinuation. 
Results 
Overall, 9702 persons were included; 5051 (52.1%) starting DTG, 1933 (19.9%) EVG, 
2718 (28.0%) RAL. The likelihood of starting RAL or EVG versus DTG decreased over 
time and was higher in Eastern and Southern Europe compared to Western Europe.  
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At 6 months after initiation, 8.9% (95% CI 8.3%-9.5%) had discontinued the INSTI 
(6.4% DTG, 7.4% EVG, 14.0% RAL). The main reason for discontinuation was toxicity 
(44.2% DTG, 42.5% EVG, 17.3% RAL). Nervous system toxicity accounted for a 
higher proportion of toxicity discontinuations on DTG (31.8% DTG, 23.4% EVG, 6.6% 
RAL). Overall, treatment simplification was highest on RAL (2.7% DTG, 1.6% EVG, 
19.8% RAL).  
Factors associated with a higher discontinuation risk included increasing year of INSTI 
initiation, female gender, hepatitis C coinfection, and prior non-AIDS defining 
malignancies. Individuals in Southern and Eastern Europe were less likely to 
discontinue. Similar results were seen for discontinuations after 6 months. 
Conclusion 
Uptake of DTG versus EVG or RAL increased over time. Discontinuation within 6 
months was mainly due to toxicity; nervous system toxicity was highest on DTG. 
Discontinuation was highest on RAL, mainly due to treatment simplification.  
 
Keywords: HIV; integrase inhibitors; dolutegravir; raltegravir; elvitegravir; toxicity 
 
Introduction 
Integrase strand transfer inhibitors (INSTIs) are one of the latest antiretroviral drug 
classes to be approved for use as part of combination antiretroviral therapy (ART) 
regimens to control HIV1. Current HIV treatment guidelines recommend that initial 
ART regimens for adults include a backbone of two nucleoside reverse transcriptase 
inhibitors (NRTIs) plus a third agent consisting of an INSTI, boosted protease inhibitor 
(PI/b) or non-nucleoside reverse transcriptase inhibitor (NNRTI)2,3. There are currently 
four INSTIs approved by the European Medicines Agency. Raltegravir (RAL)4,5 was 
the first to be approved in 2008, followed by elvitegravir (EVG)6,7 in 2013, dolutegravir 
(DTG)8–11 in 2014, and bictegravir (BIC)12,13 in 2018. 
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Commonly reported adverse effects (AEs) associated with INSTIs include headache, 
nausea, and sleep disturbances14. Additionally, cobicistat boosted EVG (EVG/c) and 
DTG may cause inhibition of renal tubular secretion of creatinine, causing an artefactual 
increase in creatinine plasma levels not reflective of a declining renal function10,15,16. 
Whilst the frequency of drug-drug interactions on INSTIs as a class is relatively low, it 
is higher on EVG, due to the need for a pharmacokinetic enhancer2 .  
Several randomised controlled trials (RCTs) have demonstrated good virological 
efficacy, fewer AEs, and lower rates of discontinuation with INSTIs compared to 
NNRTIs6,10,17–20, and PI/b7,15,21–24. These results have been confirmed in small 
observational studies14,25,26. However, despite the growing evidence, limited data exist 
on the choice of INSTIs and discontinuation of INSTIs in larger and more 
heterogeneous real-world settings. Access to individual INSTIs and reasons for 
discontinuation of INSTIs may differ among countries and subgroups, such as males 
versus females. Additionally, due to their presumed favourable safety profile, it is likely 
that a higher proportion of those with existing comorbidities are receiving INSTIs.  
We aimed to describe the characteristics of those initiating INSTIs for the first time in 
heterogeneous real-world settings across Europe and Australia. We also aimed to 
describe time to and reasons for discontinuation of initial INSTI regimens and describe 
the characteristics of those discontinuing INSTIs. 
 
Methods 
Study Design and Participants 
The International Cohort Consortium of Infectious Diseases (RESPOND) is a 
collaboration of 14 observational cohort studies across Europe and Australia, including 
26,415 individuals living with HIV-1. Demographic and clinical data were 
retrospectively collected back to 2012 and are prospectively collected from 2017.  
Standardised data including information on demographics, HIV-related factors, ART 
start and stop dates, and reason for discontinuation, coinfections, comorbidities and 
biomarkers are collected at time of enrolment and annually thereafter as part of routine 
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clinical care (details at https://www.chip.dk/Studies/RESPOND). All cohorts used the 
HIV Cohorts Data Exchange Protocol (HICDEP) for data collection (details at 
https://hicdep.org/). 
Individuals were included in this analysis if they had started DTG, EVG/c or RAL 
(persons were not necessarily ART-naïve) after the latest of local cohort enrolment and 
1st January 2012, were aged ≥ 16, and had a CD4 cell count and viral load (VL) 
measurement prior to or within 6 months after starting an INSTI. Individuals were 
excluded from the analysis if they had missing information on gender. Final follow-up 
in our study was the last clinic visit prior to 2018. 
Definition of outcomes 
The first outcome was defined as uptake of DTG, EVG/c, or RAL. Individuals starting 
more than one INSTI during follow-up were included in the first INSTI group they were 
exposed to.  
The second outcome was defined as discontinuation of first INSTI regimen during 
follow-up, provided individuals had been on the INSTI for at least 7 days (<1% of 
discontinuations occurred within 7 days of starting INSTIs). Discontinuation was not 
counted if an individual switched from a single tablet regimen (STR) to its individual 
components or vice versa, while remaining on the same INSTI, provided there was no 
interruption between treatments, nor if the backbone changed, provided the INSTI 
component remained the same. Discontinuations were split into discontinuation within 6 
months and after 6 months of INSTI initiation. 
Definition of potential predictors  
The following variables, defined prior to or at INSTI initiation, were considered as 
potential predictors: year of starting INSTI, age, gender, HIV risk category, ethnicity, 
CD4 cell count nadir, CD4 cell count at INSTI initiation, smoking status, ART 
experience and viral suppression status, viral hepatitis B and C status (HBV/HCV), 
hypertension, diabetes, AIDS defining event (ADE), non-AIDS defining malignancy 
(NADM), end stage liver disease, cardiovascular disease (CVD), fracture, chronic 
kidney disease, and geographical region. For the INSTI discontinuation models, INSTI 
type was fitted as a potential predictor.  
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CD4 cell count at INSTI initiation was taken as the most recent CD4 count before 
initiation. If no CD4 count was measured, the first measurement within 6 months after 
INSTI start was used for both CD4 at INSTI initiation and CD4 cell nadir. 
Geographical region was categorised as in previous EuroSIDA analyses27. Due to low 
numbers, Australia was combined with Northern Europe in the analysis models, and 
Eastern Central Europe was combined with Eastern Europe.  
Statistical methods 
Risk ratios using multinomial logistic regression were used to assess associations 
between baseline characteristics and the likelihood of starting RAL compared to DTG 
and of starting EVG/c compared to DTG. Baseline was defined as date of INSTI start. 
DTG was chosen as the reference category because it was the largest group and most 
recently approved INSTI. Each variable was included in univariable models and then all 
variables were fitted simultaneously in a multivariable model.  
Results of the multivariable model were compared between ART-naïve, ART-
experienced with VL<400 copies/mL and ART-experienced with VL≥400 copies/mL. 
Prespecified subgroup analyses were performed by fitting an interaction term between 
age and each of gender, HBV/HCV status, and each comorbidity listed above. 
Discontinuation of DTG, EVG/c, and RAL was summarised using Kaplan Meier (KM) 
estimates. Reasons for discontinuation of each INSTI were summarised. For each drug 
discontinuation one underlying reason was provided by the participating cohort at the 
clinician’s judgement. Reasons reported were grouped into treatment failure, toxicity, 
patient/physician choice (without further details), treatment simplification, other, and 
unknown. Discontinuations due to toxicity were further broken down into the individual 
reasons provided. Patient/physician choice was included as a marker of potential 
toxicity, as in previous EuroSIDA studies 28. 
Cox proportional hazards models were used to assess factors associated with time to 
discontinuation, including all variables listed above. Each variable was included in 
univariable models and then all were fitted simultaneously in a multivariable model. 
Individuals were censored at final follow up, defined as last clinical visit, drop out date 
as defined by the cohort, or date of death. 
AC
CE
PT
E
Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 20
8 
 
Prespecified subgroup analyses were performed between INSTI type and each of 
gender, age, HIV risk group, HBV/HCV status, and each comorbidity listed above. 
In all analysis models, an unknown category was used to account for missing data for 
categorical variables. As some cohorts were missing data on specific comorbidities, we 
did not adjust for cohort in the primary analysis. Sensitivity analyses were performed 
including cohort as an explanatory variable and excluding comorbidities. Additionally, 
the models were rerun using multiple imputation by chained equations to account for 
missing data with 10 imputations, including the same variables as those included in the 
primary analysis model. Results were combined using Rubin’s rules. 
Analyses were performed using Stata/SE 15.0. P-values are two sided and a p-value 
<0.05 was defined as statistically significant. 
 
Results 
Overall, 10,366 participants in RESPOND started an INSTI and of these, 9,702 (93.6%) 
were included in the analysis. Reasons for exclusion from the analysis are presented in 
supplementary Figure 1, http://links.lww.com/QAI/B408. Of those included, 5,051 
(52.1%) started DTG, 1,933 (19.9%) started EVG/c and 2,718 (28.0%) started RAL. Of 
those on DTG and EVG/c, 35.1% and 88.4% were on STRs, respectively. The most 
commonly used backbone for DTG was abacavir (ABC) and lamivudine (3TC) (52.0%) 
and for EVG/c and RAL tenofovir disoproxil fumarate (TDF) with emtricitabine (FTC) 
(63.4% and 49.2%, respectively).  
Baseline demographic and clinical characteristics are presented in Table 1. The majority 
of INSTI users were male, of white ethnicity and ART-experienced with a suppressed 
VL. The proportion who were ART-naïve was highest on EVG/c (30.4% on EVG/c vs 
20.5% on RAL, 23.5% on DTG, p<0.001). There was a high incidence of prior ADEs 
(21.0% on DTG, 28.3% on RAL, 13.2% on EVG/c, p<0.001) and comorbidities, 
including hypertension, diabetes, and prior CVD (proportion with at least one 
comorbidity: 37.6% on DTG, 33.1% on RAL, 27.7% on EVG/c, p<0.001). 
AC
CE
PT
ED
Copyright  20 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 20
9 
 
Uptake of INSTIs 
Results from the univariable and multivariable multinomial logistic regression models 
are presented in supplementary Table 1, http://links.lww.com/QAI/B408 and Table 2, 
http://links.lww.com/QAI/B408, respectively. After adjustment, the likelihood of 
starting RAL or EVG/c compared to DTG decreased over time. Participants in Eastern 
and Southern Europe were more likely to start RAL or EVG/c compared to those in 
Western Europe. Increasing age at INSTI initiation was associated with an increased 
likelihood of starting RAL but a decreased likelihood of starting EVG/c. Female gender 
was also associated with a decreased likelihood of starting EVG/c. The likelihood of 
starting RAL was higher for participants who were ART-naïve or ART-experienced 
with ongoing viremia compared to those who were ART-experienced with a suppressed 
VL. In general, participants with comorbidities were more likely to start RAL but less 
likely to start EVG/c compared to DTG (Table 2). Adjusting additionally for the 
nucleoside backbone did not change our findings, except HBV coinfection, which was 
no longer associated with choice of INSTI. 
We found a significant interaction between age and gender (p-value for interaction 
<0.001) for RAL vs DTG, showing that females were more likely to start RAL 
compared to men in younger age groups but were less likely to start RAL in older age 
groups (supplementary Figure 2, http://links.lww.com/QAI/B408). Other prespecified 
subgroup analyses were non-significant. Results were stratified by ART experience at 
baseline with similar findings. We repeated analyses adjusting for cohort instead of 
comorbidities with similar results. Multiple imputation to account for missing data also 
showed similar results (data not shown). As a post hoc analysis, we repeated analyses 
only including those starting an INSTI from 2015 (when DTG, EVG/c and RAL were 
available) and found similar results. 
Discontinuation of INSTIs 
Median follow-up time was longest on RAL (33.4 months IQR [16.7-48.3]), compared 
to EVG/c (17.7 [7.6-31.7]) and DTG (17.1 [8.5-26.2]). During follow up, 2,105 (21.7%) 
persons discontinued an INSTI; 619 (12.3%) discontinued DTG, 341 (17.6%) 
discontinued EVG/c, and 1,145 (42.1%) discontinued RAL. Amongst those 
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discontinuing, median time to discontinuation was 6.3 months [2.7-14.0] on DTG, 8.9 
[3.2-18.4] on EVG/c, 12.2 [4.4-24.0] on RAL. 
KM plots of discontinuation, overall and by ART-experience are shown in Figure 1. 
The overall KM estimate of discontinuation at 6 months after INSTI start was 8.9% 
(95% CI: 8.3-9.5) and highest on RAL (14.0% [12.7-15.4] vs. 6.4% [5.7-7.2] on DTG, 
7.4% [6.3-8.8] on EVG/c; p<0.001), and this was consistent between ART-naïve, ART-
experienced with VL<400 copies/mL and ART-experienced with VL≥400 copies/mL. 
Overall, the KM estimates at 1 and 2 years were 10.0% [9.1-10.9] and 15.4% [14.2-
16.7] for DTG, 13.1% [11.5-14.9] and 22.0% [19.7-24.5] for EVG/c, 22.6% [21.0-24.3] 
and 36.7% [34.7-38.7] for RAL. Discontinuation of RAL was highest in 2014 and 2015 
when DTG and EVG/c were both approved.  
Reasons for discontinuation overall, within 6 months after INSTI start, and after 6 
months after INSTI start are presented in Figure 2a. Of all discontinuations by 6 
months, the most commonly reported reason for discontinuation was toxicity (31.4% 
overall), followed by patient/physician choice (24.6% overall). Reasons for 
discontinuation were similar for DTG and EVG/c, with toxicity accounting for nearly 
half of all discontinuations in these groups (44.2% and 42.5% respectively). Conversely, 
of all discontinuations on RAL, the main reason reported was patient/physician choice 
(28.6%). Discontinuations for treatment simplification accounted for a considerably 
higher proportion of discontinuations on RAL compared to DTG or EVG/c (19.8% on 
RAL, 2.7% on DTG, 1.6% on EVG/c, p<0.001). We also compared reasons for 
discontinuation between males and females and found similar results. 
Discontinuations due to toxicity were further broken down and compared between 
INSTI types (Figure 2b). Overall 439 persons discontinued an INSTI due to toxicity 
within 6 months after INSTI initiation. Nervous system toxicity accounted for a higher 
proportion of toxicity discontinuations on DTG (31.8% on DTG, 23.4% on EVG/c, 
6.6% on RAL, p<0.001). 
Overall 1,322 (13.6%) persons discontinued an INSTI more than 6 months after INSTI 
initiation: 327 (6.5%) on DTG, 214 (11.1%) on EVG/c, 781 (28.7%) on RAL. Of those, 
the most commonly reported reason was patient/physician choice, and this was reported 
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for a similar proportion across all INSTIs (26.0%, 20.6%, 25.9% on DTG, EVG/c, and 
RAL, respectively, p=0.50). Toxicity remained the most common reason for 
discontinuation of DTG (29.7%) and EVG/c (22.4%), and treatment simplification was 
the most common reason on RAL (31.1%). 
Factors associated with discontinuation within the first 6 months are presented in Figure 
3. The adjusted risk of discontinuation was higher for RAL (hazard ratio [HR] 3.03, 
95% CI [2.47-3.70]) and EVG/c (1.37 [1.10-1.69]) compared to DTG. Individuals who 
started an INSTI later were more likely to discontinue (1.11 per year later [1.04-1.18]), 
as were females (1.28 [1.06-1.55]), those with uncontrolled viremia compared to a 
suppressed VL in ART-experienced persons (1.38 [1.08-1.75]), and those with HCV 
(1.32 [1.06-1.66]) or prior NADM (1.55 [1.13-2.12]). Conversely, those in Southern 
(0.58 [0.43-0.78]) and Eastern Europe (0.31 [0.20-0.50]) were less likely to discontinue 
compared to those in Western Europe. Full results from the univariable and 
multivariable Cox regression models are presented in supplementary Table 2, 
http://links.lww.com/QAI/B408. Similar results were seen for discontinuations greater 
than 6 months after INSTI initiation (data not shown). As post hoc analyses, we 
additionally adjusted for BMI in the multivariable model, reran analyses including those 
starting an INSTI from 2015, and looked at predictors of INSTI discontinuation due to 
toxicity only; all showed similar results. 
We found no evidence that the association between risk of discontinuation by 6 months 
and INSTI type differed according to ART-experience (p-value for interaction 0.51). 
Prespecified subgroup analyses showed a significant interaction between INSTI type 
and age group, shown in supplementary Figure 3, http://links.lww.com/QAI/B408 (p-
value for interaction 0.001). Across all age groups, the risk of discontinuation was 
higher on RAL than on DTG; however, the difference between RAL and DTG 
decreased slightly in older age groups. There was an increased risk of discontinuation of 
EVG/c compared to DTG in the oldest age group (≥50 years); however, there was no 
difference in the risk in lower age groups.  
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Discussion 
To the best of our knowledge, this is one of the first, large-scale studies investigating 
uptake and discontinuation of INSTIs in real-world settings across Europe and 
Australia. Despite being recommended as first line therapy in HIV treatment guidelines, 
scarce data exist on the choice of INSTIs used in real-world settings and data on INSTI 
discontinuation is typically limited to RCTs and smaller, national observational studies. 
This analysis of almost 10,000 persons starting an INSTI found that as the year of 
INSTI start increased, the likelihood of starting RAL or EVG/c decreased compared to 
DTG, with the greatest decline for RAL. Discontinuation was highest on RAL, mainly 
due to treatment simplification. Moreover, the proportion of individuals discontinuing 
due to toxicity was highest on DTG, although this proportion was low across all 
INSTIs. 
Subgroup analyses of INSTI uptake showed that females were more likely to start RAL 
compared to males in lower age groups but were less likely to start RAL in older age 
groups. This may partly be because RAL is recommended in treatment guidelines for 
pregnant women (or women wishing to conceive), in particular those starting follow-up 
late or whose VL is not fully suppressed at the third trimester2,29. In older age groups, 
treatment simplification may be a higher priority for menopausal women; therefore, 
regimens containing DTG are likely to be favoured over RAL. 
Furthermore, our analysis showed that those with HBV coinfection were more likely to 
start RAL or EVG/c, and those with prior CVD were also more likely to start RAL 
compared to DTG. Treatment guidelines recommend using a TDF or tenofovir 
alafenamide containing regimen in HBV coinfected individuals2,30,31. After adjustment 
for NRTI backbone the association between HBV and choice of INSTI was no longer 
significant, suggesting the backbone was likely driving this treatment choice rather than 
the INSTI. ABC has been associated with an increased risk of CVD and is commonly 
prescribed with DTG32. However, after adjusting for backbone, the association between 
CVD and the likelihood of starting RAL remained highly significant suggesting this 
decision was not driven by ABC. 
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During follow up, the risk of discontinuation was significantly higher on RAL 
compared to DTG or EVG/c, mainly due to treatment simplification. We found the rate 
of discontinuation on RAL was higher than reported in previous studies5,14,25. This is 
likely because the cut off for follow up in our study was the end of 2017, which was 
later than other studies and therefore reflects the increasing availability of newer 
INSTIs. For all INSTIs, the risk of discontinuation increased with later year of INSTI 
start, which may be related to the growing availability of post-marketing information on 
AEs associated with INSTIs and greater availability of treatment options2,3,14,33–36. 
Additionally, the risk of discontinuation was up to 3 times higher in Western Europe 
compared to other European regions, which may reflect the wider range of available 
treatment options in Western Europe37.  
The risk of INSTI discontinuation was also higher for females compared to males. This 
is in line with studies carried out by Hoffman et al.38 and Llibre et al.39, who reported an 
increased risk among females of DTG discontinuation and INSTI discontinuation due to 
AEs, respectively. Studies have suggested that the higher rates of AEs in females are 
due to a lower BMI leading to higher drug exposure38,40; however, after adjusting for 
BMI, there remained a significantly higher risk of discontinuation for females. 
Additionally, we found similar rates of discontinuation due to toxicity for females and 
males (32% and 31% of discontinuations, respectively). Our results suggest that further 
research is needed on the safety of INSTIs in females, who are often underrepresented 
in HIV research. Finally, INSTI users in older age groups were more likely to 
discontinue EVG/c compared to DTG, likely due to the increased frequency of drug 
interactions on EVG/c.  
The most common reasons for INSTI discontinuation within 6 months after INSTI start 
were patient/physician choice and toxicity. Of those starting an INSTI, the proportion 
discontinuing within 6 months due to toxicity was relatively low on all INSTIs (3.9% 
DTG, 4.0% EVG/c, 6.1% RAL). This is an important and reassuring real-world finding 
showing that toxicities are not leading to high rates of INSTI discontinuation. The most 
common individual toxicity was from the nervous system for DTG and EVG/c and from 
the abdomen/gastrointestinal tract for RAL. This is in line with several observational 
studies that have reported higher rates of DTG discontinuation due to neuropsychiatric 
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AEs compared to other INSTIs14,25,38,39,41–43. As is the case with several recent 
observational studies and case reports38,39,41–46, our results show a higher rate of 
discontinuation due to toxicity than reported in RCTs, especially on DTG. This likely 
reflects the selected population participating in RCTs and reflects the need for further 
investigation. Beyond 6 months after INSTI initiation, the most common toxicity for 
EVG/c was renal, likely attributable to the coformulation with TDF in the STR 
TDF/FTC/EVC/c and the increase in creatinine caused by cobicistat47. 
Our study has several limitations. Persons enrolled in RESPOND were not randomly 
selected as we pre-specified the minimum number of participants on INSTIs to be 
included in the cohort collaboration, and it is not possible to rule out confounding by 
indication or to fully adjust for all factors associated with choice and discontinuation of 
INSTIs. As is common with observational studies, there is a relatively high proportion 
of missing data, particularly for comorbidities. However, sensitivity analyses using 
multiple imputation to account for missing data showed similar results. Follow up for 
DTG in particular, may still be limited as the data cut-off for this analysis was the end 
of 2017. The reasons for discontinuation of INSTIs are those reported in patient notes 
and the proportion of unknown reasons, as well as the distribution of known reasons, 
differs considerably between cohorts. Only one reason was provided per 
discontinuation, and the reasons given are limited, for example, patient/physician choice 
may cover a wide range of reasons including concerns about toxicity, drug interactions, 
and adherence, however we did not have access to any further information. However, all 
cohorts used the HICDEP standard for reporting and have previously participated in the 
development of this standard. Finally, we did not collect data on non-antiretroviral 
treatment or pre-existing mental illness, which may affect the choice and 
discontinuation risk of INSTIs. 
In conclusion, uptake of DTG compared to EVG/c or RAL has increased over calendar 
time, and more in Western Europe compared to other European regions. INSTI 
discontinuation was mainly due to toxicity in the first 6 months and patient/physician 
choice thereafter, but was low overall. Discontinuation was significantly higher for 
RAL, mainly due to treatment simplification, whilst discontinuation due to nervous 
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system toxicities was highest on DTG. Our findings highlight the need for further 
research to better understand AEs on INSTIs. 
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Figure Legends 
Figure 1. Kaplan Meier plots of INSTI discontinuation: (a) overall; (b) in ART 
naïve individuals; (c) in ART experienced individuals with a viral load < 400 
copies/mL; (d) in ART experienced individuals with a viral load ≥ 400 copies/mL 
 
Figure 2 (a) Reasons for INSTI discontinuation; (b) Reasons for toxicity 
discontinuation; split by discontinuations ≤6 months and >6 months after INSTI 
start 
Abbreviations: G-I – gastrointestinal; INSTI - integrase inhibitor 
Discontinuation was not counted if the backbone changed or participants went from a 
single tablet regimen to individual components or vice versa, provided the INSTI 
component of the regimen remained the same 
Other includes pregnancy, availability of more effective treatment, drug interaction, 
protocol change, regular treatment termination, end of empiric treatment, structured 
treatment interruption, study treatment commenced or completed.  
Treatment failure includes virological failure, immunological failure, clinical 
progression, death; if the discontinuation reason was reported as other causes or 
unknown and the viral load at discontinuation (± 3 months) was greater than 400 
copies/mL, this was counted as treatment failure.  
Simplified treatment available includes simplified treatment available, treatment too 
complex;  
Toxicity includes abnormal fat redistribution, concern of cardiovascular, 
hypersensitivity reaction, abdomen or gastrointestinal tract toxicity, nervous system 
toxicity, kidney toxicity, endocrine system toxicity, unspecified side effects; 
Figure 3. Significant associations between baseline characteristics and INSTI 
discontinuation in the first 6 months after INSTI start 
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Table 1 Baseline characteristics of persons starting INSTIs in RESPOND, overall and by 
INSTI type - n (%) unless stated otherwise 
Overall Dolutegravir Raltegravir Elvitegravir 
Total   9702 (100) 5051 (52.1) 2718 (28.0) 1933 (19.9) 
Geographical 
region 
Western Europe 5146 (53.0) 3025 (59.9) 1046 (38.5) 1075 (55.6) 
Southern Europe 2679 (27.6) 1318 (26.1) 728 (26.8) 633 (32.7) 
Northern Europe 1275 (13.1) 453 (9.0) 697 (25.6) 125 (6.5) 
Eastern Europe 490 (5.1) 216 (4.3) 176 (6.5) 98 (5.1) 
Eastern Central 
Europe 112 (1.2) 39 (0.8) 71 (2.6) 2 (0.1) 
Australia 119 (1.2) 52 (1.0) 40 (1.4) 27 (1.4) 
Gender 
Male 7322 (75.5) 3765 (74.5) 1998 (73.5) 1559 (80.7) 
Female 2378 (24.5) 1286 (25.5) 720 (26.5) 372 (19.2) 
Transgender 2 (0.0) 0 (0.0) 0 (0.0) 2 (0.1) 
Ethnic Origin* 
White 6835 (82.6) 3691 (84.1) 1875 (81.2) 1269 (80.6) 
Black 1023 (12.4) 482 (11.0) 325 (14.1) 216 (13.7) 
Other  417 (5.0) 218 (5.0) 110 (4.8) 89 (5.7) 
BMI* 
<18.5 369 (5.4) 203 (5.2) 107 (7.0) 59 (4.2) 
18.5-<25 3887 (56.9) 2233 (57.2) 859 (56.0) 795 (56.9) 
≥25 2580 (37.7) 1469 (37.6) 569 (37.1) 542 (38.8) 
Smoking 
status* 
Never 2451 (40.8) 1402 (41.3) 548 (39.2) 501 (41.4) 
Current 2627 (43.8) 1488 (43.8) 607 (43.4) 532 (44.0) 
Previous 924 (15.4) 505 (14.9) 243 (17.7) 176 (14.6) 
ART experience 
Naïve 2330 (24.0) 1185 (23.5) 557 (20.5) 588 (30.4) 
Experienced, VL < 
400 cps/mL 6541 (67.4) 3529 (69.9) 1798 (66.2) 1214 (62.8) 
Experienced, VL ≥ 
400 cps/mL 831 (8.6) 337 (6.7) 363 (13.4) 131 (6.8) 
HIV risk* 
MSM 4356 (47.5) 2244 (47.0) 1121 (43.3) 991 (54.7) 
IDU 1396 (15.2) 735 (15.4) 460 (17.8) 201 (11.1) 
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Heterosexual 3164 (34.5) 1669 (35.0) 911 (35.2) 584 (32.2) 
Other  256 (2.8) 124 (2.5) 95 (3.5) 37 (2.0) 
Hepatitis C*
,1
   2193 (22.6) 1174 (23.2) 714 (26.3) 305 (15.8) 
Hepatitis B*
,2
   439 (4.5) 189 (3.7) 148 (5.4) 102 (5.3) 
Hypertension*
,4
   2264 (23.3) 1341 (26.5) 536 (19.7) 387 (20.0) 
Diabetes*   763 (7.9) 398 (7.9) 242 (8.9) 123 (6.4) 
Prior AIDS*   2085 (21.5) 1061 (21.0) 768 (28.3) 256 (13.2) 
Prior NADM*   382 (3.9) 210 (4.2) 134 (4.9) 38 (2.0) 
Prior ESLD*   83 (0.9) 37 (0.7) 40 (1.5) 6 (0.3) 
Prior CVD*
,5
   344 (3.5) 152 (3.0) 149 (5.5) 43 (2.2) 
Prior fracture*   458 (4.7) 261 (5.2) 125 (4.6) 72 (3.7) 
Prior CKD*
,6
   359 (3.7) 196 (3.9) 125 (4.6) 38 (2.0) 
Continuous variables, median (IQR) 
INSTI start date   
Aug 
2015 
(Sept 2014, 
Jul 2016) 
Jan 
2016 
(May 2015, 
Oct 2016) 
Feb 
2014 
(Jan 2013, 
Apr 2015) 
Dec 
2015 
(Oct 2014, 
Nov 2016) 
Age, years   48 (39, 54) 48 (39, 55) 48 (41, 54) 45 (36, 53) 
CD4 cell nadir, 
cells/mm³   213 (91, 350) 215 (93, 349) 179 (68, 311) 262 (138, 404) 
CD4 at INSTI 
start, cells/mm³   552 (350, 761) 578 (369, 788) 507 (297, 714) 560 (386, 756) 
Abbreviations: INSTI-integrase inhibitor; BMI-body mass index; ART-antiretroviral treatment; VL-viral load; MSM-
men who have sex with men; IDU-intravenous drug user; NADM-non-AIDS defining malignancy; ESLD-end stage liver 
disease; CVD-cardiovascular disease; CKD-chronic kidney disease; IQR-interquartile range 
Baseline is defined as the date of starting an INSTI 
1
HCV was defined by use of anti-HCV medication, a positive HCV antibody test, a positive HCV RNA qualitative test, 
HCV RNA-VL >615 IU/mL, and/or a positive genotype test.  
2
HBV was defined by a positive HBV surface antigen test and/or HBV RNA-VL >357 IU/mL. 
4
Hypertension was confirmed by use of anti-hypertensives at any time before INSTI start or if the most recent blood 
pressure measurement before INSTI start was higher than 140/90 mmHg. 
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5
CVD was a centrally adjudicated event defined using a composite diagnosis of myocardial infarction, stroke or 
invasive cardiovascular procedure.  
6
CKD was confirmed if there were two consecutive measurements of estimated glomerular filtration rate (eGFR) 
<60 mL/min measured at least 3 months apart. eGFR was calculated using the CKD-EPI creatinine equation (47). 
*Denominator for percentages is all participants with non-missing data. 
Total unknown n (%): Ethnicity 1454 (14.8) BMI 2875 (29.2), Smoking status 3763 (38.3), HIV risk 535 (5.4), hepatitis 
C 1417 (14.4), hepatitis B 1672 (17.0), hypertension 2864 (29.1), diabetes 917 (9.3), prior AIDS 1143 (11.6), prior 
NADM 1995 (20.3), prior ESLD 5641 (57.4), prior CVD 2672 (27.2), prior fracture 2889 (29.4), prior CKD 1762 (17.9). 
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Table 2 Associations between characteristics at INSTI start and choice of INSTIs – 
multivariable analysis  
Raltegravir vs Dolutegravir Elvitegravir vs Dolutegravir 
Variable Reference Group RR* (95% CI) p-value RR* (95% CI) p-value 
INSTI start, per 1  
calendar year later  
0.25 (0.23, 0.26) <0.001 0.81 (0.77, 0.85) <0.001 
Geographical 
region
1
 
Western 
Europe 
Southern Europe 3.00 (2.36, 3.81) <0.001 1.23 (0.99, 1.52) <0.001 
Northern Europe/ 
Australia 1.15 (0.86, 1.52)  0.68 (0.52, 0.90)  
Eastern Europe 6.82 (5.07, 9.19)  1.36 (1.02, 1.81)  
Age, per 10-
year increase 
 
1.14 (1.06, 1.22) <0.001 0.91 (0.86, 0.97) 0.002 
Gender Male Female 0.98 (0.82, 1.17) 0.80 0.68 (0.58, 0.80) <0.001 
Ethnic origin† White Black 1.00 (0.77, 1.30) 0.99 1.24 (1.00, 1.54) 0.11 
  Other 0.98 (0.68, 1.42)  1.14 (0.87, 1.50)  
Smoking status† Never 
Current 1.03 (0.85, 1.24) 0.82 1.10 (0.94, 1.29) 0.46 
Previous 1.08 (0.85, 1.38)  1.04 (0.84, 1.28)  
ART experience 
Experienced, 
VL<400 
cps/mL 
Naive 1.29 (1.03, 1.63) <0.001 0.99 (0.82, 1.19) 0.61 
Experienced, 
VL≥400 cps/mL 
1.56 (1.22, 2.00)  1.12 (0.88, 1.41) 
 
HIV risk† MSM 
IDU 1.37 (1.06, 1.76) 0.004 1.01 (0.80, 1.28) 0.53 
Heterosexual 1.33 (1.10, 1.60)  1.10 (0.94, 1.29)  
  Other 1.69 (1.11, 2.57)  0.88 (0.59, 1.32)  
CD4 nadir, 
cells/mm³ 
<200 
200-349 0.97 (0.81, 1.16) 0.57 1.09 (0.94, 1.27) 0.70 
350-499 0.93 (0.73, 1.18) 1.07 (0.88, 1.31) 
≥500 1.14 (0.85, 1.53) 1.06 (0.84, 1.35) 
CD4 at  
INSTI start, 
cells/mm³ 
<200 
200-349 0.92 (0.70, 1.21) 0.16 1.75 (1.34, 2.27) <0.001 
350-499 0.84 (0.64, 1.10) 1.88 (1.45, 2.44) 
≥500 0.76 (0.58, 0.99) 1.66 (1.27, 2.17) 
Hepatitis C† No Yes 1.39 (1.13, 1.72) 0.002 0.80 (0.66, 0.98) 0.03 
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Hepatitis B† No Yes 1.60 (1.19, 2.17) 0.002 1.68 (1.30, 2.19) <0.001 
Hypertension† No Yes 0.90 (0.76, 1.07) 0.24 0.85 (0.73, 0.98) 0.03 
Diabetes† No Yes 1.20 (0.95, 1.51) 0.13 1.07 (0.85, 1.34) 0.58 
Prior AIDS† No Yes 1.29 (1.09, 1.52) 0.003 0.71 (0.60, 0.84) <0.001 
Prior NADM† No Yes 1.23 (0.89, 1.70) 0.21 0.67 (0.47, 0.97) 0.03 
Prior ESLD† No Yes 1.38 (0.74, 2.59) 0.31 0.54 (0.21, 1.42) 0.21 
Prior CVD† No Yes 2.34 (1.69, 3.24) <0.001 1.00 (0.70, 1.44) 0.99 
Prior fracture† No Yes 0.60 (0.43, 0.83) 0.002 1.06 (0.80, 1.40) 0.67 
Prior CKD† No Yes 1.32 (0.94, 1.83) 0.11 0.76 (0.52, 1.10) 0.14 
Abbreviations: RR-risk ratio; CI- confidence interval; INSTI-integrase inhibitor; ART-antiretroviral treatment; MSM-
men who have sex with men; IDU-intravenous drug user; VL-viral load; NADM-non-AIDS defining malignancies; 
ESLD-end stage liver disease; CVD-cardiovascular disease; CKD-chronic kidney disease 
*Results from a multivariable, multinomial logistic regression; all variables were fitted in the model simultaneously 
1
Due to low counts, Australia is grouped with Northern Europe and Eastern Central Europe is grouped with Eastern 
Europe. 
†
Missing data fitted as an unknown category (data not shown) 
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